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Oral squamous cell carcinoma (SCC) has a striking tendency to
invade to bone. The chemokine stromal cell-derived factor-1
(SDF-1) is constitutively secreted by osteoblasts and plays a key
role in homing of hematopoietic cells to the bone marrow. Inter-
leukin (IL)-6 plays an important role in osteoclastogenesis.
Herein, we found that SDF-1a increased the secretion of IL-6 in
cultured human SCC cells, as shown by reverse transcriptase–
polymerase chain reaction and enzyme-linked immunosorbent
assay. SDF-1a also increased the surface expression of chemokine
receptor 4 (CXCR4) in SCC cells. CXCR4-neutralizing antibody,
CXCR4-speciﬁc inhibitor (AMD3100) or small interfering RNA
against CXCR4 inhibited SDF-1a-induced increase IL-6 produc-
tion. The transcriptional regulation of IL-6 by SDF-1a was me-
diated by phosphorylation of extracellular signal-regulated
kinases (ERKs) and activation of the nuclear factor-kappa B
(NF-kB) components p65 and p50. The binding of p65 and p50
to the NF-kB element on the IL-6 promoter was enhanced by
SDF-1a. In addition, IL-6 antibody antagonized the SCC-
conditioned medium-increased osteoclastogenesis. These results
suggested that SDF-1a from osteoblasts could induce release
of IL-6 in human SCC cells via activation of CXCR4, ERK and
NF-kB pathway and thereby promote osteoclastogenesis.
Introduction
Oral squamous cell carcinoma (SCC) represents 1–2% of all human
malignancies. They are characterized by a high degree of local in-
vasiveness and a high rate of metastasis to cervical lymph nodes, but
a low rate of metastasis to distant organs. The invasion of oral SCC
into maxillary and mandibular bone is a common clinical problem.
The process of invasion consists of well-linked multiple tumor–host
interactions. Previous reports suggest that bone destruction in
carcinoma invasion and metastasis is mediated by osteoclasts rather
than by carcinoma cells directly (1–3).
Interleukin (IL)-6, originally identiﬁed as a T-cell-derived cytokine
that induces ﬁnal maturation of B cells into antibody-producing cells
(4), exhibits multiple biological activities that differ widely among
various types of tissues and cells. Many investigators have reported
that IL-6 can enhance or inhibit the proliferation of carcinoma cells
(5–9) and that a variety of malignant tumors, including SCCs and
adenocarcinomas, have been shown to contain or synthesize IL-6,
and autocrine growth stimulation has been suggested as the possible
mechanism for the action of IL-6 (10–12). Furthermore, IL-6 also has
unique and important effects on bone cells (13). It increases the for-
mation of cells with osteoclast characteristics that have the capacity
to resorb bone (14,15). It has also been reported that neutralizing
antibody against human IL-6 reversed hypercalcemia associated
with human squamous carcinoma by inhibiting osteoclastic bone
resorption (16).
Chemokines are structurally related, small (8–14 kDa) polypeptide
signaling molecules, which bind to and activate a family of seven-
transmembrane G-protein-coupled receptors, the chemokine receptors
(17,18). Chemokines are expressed by many tumor types and can
promote mitosis and modulate apoptosis, survival and angiogenesis
(19,20). Interaction between the chemokine receptor CXCR4 and its
ligand, stromal cell-derived factor 1a (SDF-1a or CXCL12), has been
found to play an important role in tumorigenicity, proliferation,
metastasis and angiogenesis in many cancers, such as lung cancer,
breast cancer, melanoma, glioblastoma, pancreatic cancer, cholangio-
carcinomaandbasalcell carcinoma cells (21–24). Although the mech-
anisms underlying SDF-1a/CXCR4-mediated tumor invasion have
been studied in some cancers (21–24), the role of SDF-1a/CXCR4
in the process of SCC cells invasion to bone remains largely unknown.
Bone is a common site of cancer metastasis. Several tumors show
a particular predilection for metastasis to bone, including breast, pros-
tate and lung cancers. Bone-derived growth factor and chemokines
also play central roles as trophic factors that attract breast and prostate
cancer cells to bone tissue (25). It has been reported that the chemo-
kine IL-6 is a potent and direct activator of osteoclastic differentiation
and bone resorption (25). The SDF-1, constitutively secreted by
human osteoblast, has been shown to have a key role in the homing
of hematopoietic cells to marrow (26). We hypothesized that osteo-
blast-derived SDF-1 could be capable of regulating IL-6 levels and
promoting osteoclastogenesis in SCC cells. The results show that
osteoblasts-derived SDF-1 activates CXCR4 receptor and results in
the activation of extracellular signal-regulated kinase (ERK)/IjB ki-
nase ab (IKKab) and nuclear factor-kappa B (NF-jB), leading to
upregulation of IL-6 expression and promoting osteoclastogenesis.
Materials and methods
Materials
Protein A/G beads, anti-mouse and anti-rabbit IgG-conjugated horseradish per-
oxidase, rabbit polyclonal antibodies speciﬁc for IjBa, p-IjBa, IKKa/b, p65,
p50, p-ERK, p-p38, p-JNK, p-Akt, ERK, p38, c-Jun N-terminal kinase (JNK)
and Akt were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Rabbit polyclonal antibody speciﬁc for IKKa/b phosphorylated at Ser180/181
and p65 phosphorylated at Ser276 was purchased from Cell Signaling
and Neuroscience (Danvers, MA). Pyrrolidine dithiocarbamate (PDTC), L-1-
tosylamido-2-phenylenylethyl chloromethyl ketone, PD98059, SB203580,
SP600125 and Akt inhibitor (1L-6-hydroxymethyl-chiro-inositol-2-[(R)-2-O-
methyl-3-O-octadecylcarbonate]) were obtainedfrom Calbiochem(San Diego,
CA). Rabbit polyclonal antibody speciﬁc for CXCR4, IL-6, IL-1, transforming
growth factor-b and receptor activator of nuclear factor-kappa B ligand
(RANKL)-Fc were purchased from R&D Systems (Minneapolis, MN). The
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(residues 360–369) of the transcription factor NF-jB p50 linked to a peptide
cell-permeabilization sequence] was purchased from BIOMOL (Butler Pike,
PA). The recombinant human SDF-1a was purchased from PeproTech (Rocky
Hill, NJ). IL-6 enzyme immunoassay kit was purchased from Cayman Chem-
ical (Ann Arbor, MI). The NF-jB luciferase plasmid was purchased from
Stratagene (La Jolla, CA). The human full-length CXCR4 was provided by
Dr Jun Komano (National Institute of Infectious Diseases, Japan). The p38
dominant-negative mutant was provided by Dr J. Han (South-western Medical
Center, Dallas, TX). The JNK dominant-negative mutant was provided by Dr
M. Karin (University of California, San Diego, CA). The ERK2 dominant-
negative mutant was provided by Dr M. Cobb (South-Western Medical Cen-
ter). The IKKa–KM(K44A) and IKKb KM(K44A) mutants were gifts from
Dr H. Nakano (Juntendo University, Tokyo, Japan) (27). The Akt (Akt K179A)
mutant was a gift from Dr R. H. Chen (Institute of Molecular Medicine,
National Taiwan University, Taipei, Taiwan). pSV-b-galactosidase vector, lu-
ciferase assay kit, was purchased from Promega (Madison, WI). All other
chemicals were obtained from Sigma-Aldrich (St Louis, MO).
Cell culture
The human oral SCC cell lines (HSC3,SCC4, SCC9)and human osteosarcoma
cell line (MG-63) were obtained from the American Type Culture Collection
(Rockville, MD). The cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium that was supplemented with 20 mM N-2-hydroxyethylpiperazine-N#-
2-ethanesulfonic acid and 10% heat-inactivated fetal calf serum, 2 mM glutamine,
penicillin (100 U/ml) and streptomycin (100 lg/ml) at 37C with 5% CO2.
Forty-eight hour-conditioned medium (containing serum) from SCC4 cells
were collected, diluted 50% in Dulbecco’s modiﬁed Eagle’s medium and
added to cultures of human peripheral blood mononuclear cells (PBMCs) to
induce osteoclastogenesis (28).
Isolation and culture of PBMCs and differentiation to osteoclasts
Peripheral blood was collected from healthy donors with heparin anticoagu-
lant, in the presence of 200 ng/ml RANK-Fc, to minimize any priming of
osteoclast progenitors by endogenous RANKL as described (28). Blood was
diluted in sterile phosphate-buffered saline (PBS) (1:1) in a sterile hood. The
blood-PBS solution was slowly layered over Accu-Prep solution (Accurate
Chemical and Scientiﬁc, Westbury, NY) and then centrifuged at 400g in swing
buckets for 30 min at 21C. The PBMC layer was collected and washed in ﬁve
to six volumes of PBS, isolated by centrifugation at 140g and resuspended in
a-minimum essential medium containing 10% fetal bovine serum. Cells were
counted with a hemocytometer and plated in 48-well tissue culture plates at
a concentration of 0.5 million cells in 0.5 ml volume per well. Macrophage
colony-stimulating factor-1 (25 ng/ml) was added to all groups. RANKL (25
ng/ml) was used as a positive control. Cultures were maintained at 37C and
half-feeds were done thrice per week and terminated on day 10. Medium was
aspirated and the cells were ﬁxed with 10% formalin. Tartrate-resistant acid
phosphatase (TRAP) staining was done (Sigma) for quantitation of TRAP-
positive multinucleated cells. TRAP-positive cells with more than three nuclei
were counted as osteoclasts in the entire well with four wells per treatment.
Cell counts were averaged and the results were expressed as the number of
TRAP-positive multinucleated cells per well per treatment group (28).
Measurements of IL-6 production
Human SCC cells were cultured in 24-well culture plates. After reaching
conﬂuence, cells were treated with SDF-1a and incubated in a humidiﬁed
incubator at 37C for 24 h. For examination of the downstream signaling
pathways involved in SDF-1a treatment, cells were pretreated with various
inhibitors for 30 min before SDF-1a (100 ng/ml) administration. After incu-
bation, the medium was removed and stored at  80C until assay. IL-6 in the
medium was assayed using IL-6 enzyme immunoassay kits, according to the
procedure described by the manufacturer.
Messenger RNA analysis by reverse transcriptase–polymerase chain reaction
Total RNA was extracted from SCC cells using a TRIzol kit (MdBio, Inc.,
Taipei, Taiwan). The reverse transcription reaction was performed using 2 lg
of total RNA that was reverse transcribed into cDNA using oligo(dT) primer,
then ampliﬁed for 33 cycles using two oligonucleotide (ODN) primers—IL-6:
AAATGCCAGCCTGCTGACGAAG and AACAACAATCTGAGGTGCCC-
ATGCTAC; CXCR4: AATCTTCCTGCCCACCATCT and GACGCCAACAT
AGACCACCT; GAPDH: AAGCCCATCACCATCTTCCAG and AGGGGC-
CATCCACAGTCTTCT.
Each polymerase chain reaction (PCR) cycle was carried out for 30 s at
94C, 30 s at 55C and 1 min at 68C.
PCR products were then separated electrophoretically in a 2% agarose DNA
gel and stained with ethidium bromide.
Western blot analysis
The cellular lysates were prepared as described previously (29). Proteins were
resolved on sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
transferred to Immobilon polyvinyl diﬂuoride membranes. The blots were
blocked with 4% bovine serum albumin for 1 h at room temperature and
probed with rabbit anti-human antibodies against IjBa,I K K ab, p65 or p50
(1:1000) for 1 h at room temperature. After three washes, the blots were sub-
sequently incubated with a donkey anti-rabbit peroxidase-conjugated secondary
antibody (1:1000) for 1 h at room temperature. The blots were visualized by
enhanced chemiluminescence using Kodak X-OMAT LS ﬁlm (Eastman Kodak,
Rochester, NY). Quantitative data were obtained using a computing densitom-
eter and ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
Flow cytometric analysis
Human SCC cells were plated in six-well dishes. The cells were then washed
with PBS and detached with trypsin at 37C. Cells were ﬁxed for 10 min in
PBS containing 1% paraformaldehyde. After rinsing in PBS, the cells were
incubated with rabbit anti-human antibody against CXCR4 (1:100) for 1 h at
4C.Cellswerethenwashed again and incubated with ﬂuoresceinisothiocyanate-
conjugated goat anti-rabbit secondary IgG (1:150; Leinco Tec., Inc., St Louis,
MO)for45minandanalyzedbyﬂowcytometryusingFACSCaliburandCellQuest
software (BD Biosciences, San Jose, CA) (30).
Transfection and reporter gene assay
Human SCC cells were cotransfected with 0.8 lg jB-luciferase plasmid and
0.4 lg b-galactosidase expression vector. Cells were grown to 80% conﬂuence
in 12-well plates and transfected the following day by Lipofectamine 2000
(Invitrogen, Carlsbad, CA). DNA and Lipofectamine 2000 were premixed for
20 min and then applied to the cells. After 24 h transfection, the cells were
incubated with the indicated agents. After further 24 h incubation, the media
were removed, and cells were washed once with cold PBS. To prepare lysates,
100 ll reporter lysis buffer (Promega) was added to each well, and cells were
scraped from dishes. The supernatant was collected after centrifugation at
13 000 r.p.m. for 2 min. Aliquots of cell lysates (20 ll) containing equal
amounts of protein (20–30 lg) were placed into wells of an opaque black
96-well microplate. An equal volume of luciferase substrate was added to all
samples, and luminescence was measured in a microplate luminometer. The
value ofluciferaseactivity wasnormalizedto transfection efﬁciency monitored
by the cotransfected b-galactosidase expression vector.
Synthesis of NF-jB and AP-1 decoy ODNs
We used a phosphorothioate double-stranded decoy ODN carrying the NF-jB/
Rel-consensus sequence 5#-CCTTGAA GGGATTTCCCTCC-3#/3#-GGAAC-
TTCCCTAAAGGGAGG-5#. The activator protein-1 (AP-1) decoy ODN
sequence was 5#-TGTCTGACTCATGTC-3#/3#-ACAGACTGAGTACAG-5#.
The mutated (scrambled) form 5#-TTGCCGTACCTGACTTAGCC-3#/3#-
AACGGCATGGACTGAATCGG-5# was used as a control. ODN (5 lM)
was mixed with Lipofectamine 2000 (10 lg/ml) for 25 min at room temper-
ature, and the mixture was added to cells in serum-free medium. After 24 h of
transient transfection, the cells were used for the following experiments (31).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation analysis was performed as described previ-
ously (32). DNA immunoprecipitated by anti-p65 or anti-p50 antibody was
puriﬁed. The DNA was then extracted with phenol–chloroform. The puriﬁed
DNA pellet was subjected to PCR. PCR products were then resolved by 1.5%
agarose gel electrophoresis and visualized by UV.
The primers 5#-CAAGACATGCCAAAGTGCTG-3# and 5#-TTGAGACT-
CATGGGAAAATCC-3# were utilized to amplify across the human IL-6 pro-
moter region ( 288 to  39) (33).
Statistics
Thevalues given are means ± SEM. The signiﬁcance of difference between the
experimental groups and controls was assessed by Student’s t-test. The differ-
ence was signiﬁcant if the P value was ,0.05.
Results
SDF-1 induces IL-6 production in human oral cancer cells
SDF-1 is a powerful chemoattractant cytokine that stimulates direc-
tional migration of hematopoietic and non-hematopoietic cells.
We hypothesized that osteoblast-derived SDF-1 could be capable of
regulating IL-6 levels and promoting osteoclastogenesis in SCC
cells. Figure 1A shows that SDF-1a induced the expression of IL-6
messenger RNA (mRNA) and protein levels in SCC cells (HSC3,
C.-H.Tang et al.
1484SCC4 and SCC9). Treatment of SCC cells with SDF-1a (100 ng/ml)
for 24 h induced IL-6 production in a concentration-dependent manner
(Figure 1B), and this induction occurred in a time-dependent manner
(Figure 1C). After SDF-1a (100 lg/ml) treatment for 24 h, the amount
of IL-6 released had increased in oral cancer cells (Figure 1C).
To further conﬁrm this stimulation-speciﬁc mediation by SDF-1a
without lipopolysaccharide contamination, polymyxin B, a lipopoly-
saccharide inhibitor, was used. We found that polymyxin B (1 lM)
completely inhibited lipopolysaccharide (1 lM)-induced IL-6 release.
However, it had no effect on SDF-1a (100 ng/ml)-induced IL-6 re-
lease in SCC4 cells (Figure 1D).
SDF-1a–CXCR4 interaction directs the expression of IL-6 in SCC
cells
Interaction of SDF-1 with its speciﬁc receptor CXCR4 on the surface
of prostate cancer cells has been reported to induce the release of
cytokine (34). We examined whether SDF-1–CXCR4 interaction
was involved in the signal transduction pathway leading to IL-6
Fig. 1. SDF-1a induced IL-6 production in human SCC cells. (A) Human SCC cells (HSC3, SCC4, SCC9) were incubated with SDF-1a (100 ng/ml); the mRNA
orproteinlevelofIL-6were determined byusingreverse transcriptase–polymerasechain reaction(RT–PCR)orwesternblotanalysis,respectively.SCC cells were
incubated with various concentrations of SDF-1a for 24 h (B) or with SDF-1a (100 ng/ml) for 4, 8, 12, 18 or 24 h (C). Media were collected to measure IL-6.
Results of four independent experiments performed in triplicate are expressed.  P , 0.05 as compared with basal level. (D) SCC4 cells were pretreated with
polymyxin B (poly B, 1 lM) for 30 min followed by stimulation with lipopolysaccharide (LPS) (1 lM) or SDF-1a (100 ng/ml) for 24 h. Media were collected to
measure IL-6. Results offour independent experiments performed in triplicate are expressed.  P , 0.05 as compared with basal level. #P , 0.05 as compared with
LPS- or SDF-1a-treated group. (E) SCC4 cells were incubated with SDF-1a (100 ng/ml) for indicated time intervals, and cell lysates were then collected, and the
mRNAorproteinlevelofCXCR4was determinedbyusingRT–PCRorwesternblot analysis,respectively.(F) SCC4cellswereincubatedwith SDF-1a (100ng/ml)
for indicated time intervals, and the cell surface expression of CXCR4 was determined by using ﬂow cytometry. (G) SCC4 cells were transfected with human full-
length CXCR4 or vector for 48 h; the protein level of CXCR4 was determined using western blot analysis. (H) SCC4 cells were transfected with human full-length
CXCR4 or vector for 48 h and then incubated with SDF-1a for 24 h. Media were collected to measure IL-6. Results of four independent experiments performed in
triplicate are expressed.
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1485expression caused by SDF-1a. Human SCC cells were treated with
SDF-1a for different time intervals, and cell lysates were collected.
The results from reverse transcriptase–PCR, western blot and ﬂow
cytometry indicated that SDF-1a signiﬁcantly increased mRNA and
protein levelsand cell surface expression of CXCR4 time dependently
(Figure 1E and F). Transfection of SCC4 cells with human full-length
CXCR4 increased the CXCR4 expression by western blot analysis
(Figure 1G). In addition, overexpression of human full-length CXCR4
increased the SDF-1a-induced IL-6 expression in human SCC cells
(Figure 1H). Pretreatment of SCC4 cells for 30 min with CXCR4-
speciﬁc chemical inhibitor AMD3100 (200, 500 ng/ml), CXCR4-
neutralizing antibody (12G5) (10 lg/ml) but not mouse monoclonal
immunoglobulin isotype control (isotype antibody) (10 lg/ml) antag-
onized the SDF-1a-induced IL-6 expression (Figure 2A). Small
interferingRNA(siRNA)againstCXCR4(siCXCR4),butnotamutant
form of siCXCR4, speciﬁcally inhibited mRNA and protein levels of
CXCR4, respectively (Figure 2B). Transient transfection of siCXCR4
but not a mutant form of siCXCR4 effectively inhibited the expression
of IL-6 directed by SDF-1a (Figure 2C). On the other hand, the oste-
oblast-conditionedmediuminducedthemRNAandproteinexpression
of IL-6 that was reduced by siCXCR4 but not a mutant form of
siCXCR4 (Figure 2D). It is well established that osteoblasts cells
can synthesize and secrete SDF-1a, which plays an important role
in prostate cancer metastasizing to bone (33). Human osteoblasts cells
(MG-63) were transfected with the control or SDF-1 siRNA, after
whichtheirosteoblast-conditionedmediumwascollected.Theexpres-
sion of SDF-1 was suppressed by transfection with SDF-1 siRNA
(Figure 2E). Additionally, SDF-1 siRNA could markedly block the
Fig. 2. SDF-1a/CXCR4 mediated the SDF-1a-induced IL-6 expression. (A) SCC4 cells were pretreated with AMD3100 (200, 500 ng/ml), CXCR4-neutalizing
antibody (12G5; 10 lg/ml) and mouse monoclonal immunoglobulin isotype control (isotype antibody; 10 lg/ml) for 30 min. Mediawere collected to measure IL-6.
(B) SCC4 cells were transfected with a mutant form of siCXCR4 or siCXCR4 for 24 h; the mRNA and protein levels of CXCR4 were determined using reverse
transcriptase–polymerase chain reaction (RT–PCR) or western blot analysis, respectively. (C and D) SCC4 cells were transfected with siCXCR4 or a mutant form
of siCXCR4 siRNA for 24 h followed by stimulation with SDF-1a (100 ng/ml) or osteoblast-conditioned medium (OBCM; 75%). The medium or mRNA and
protein levels of IL-6 were determined by using enzyme-linked immunosorbent assay or RT–PCR and western blot, respectively. (E) Osteoblasts (MG-63) were
transfected with SDF-1a or control siRNA for 24 h. The mRNA or protein level of SDF-1a determined by using RT–PCR and western blot analysis were
suppressed after transfection with SDF-1 siRNA. (F) Osteoblasts cells were transfected with SDF-1a or control siRNA for 24 h, the medium was collected as
conditioned medium then apply to SCC4 cells and the mRNA or protein level of IL-6 was measured by using RT–PCR or western blot analysis, respectively.
C.-H.Tang et al.
1486osteoblast-conditioned medium-induced expression of IL-6 in SCC4
cells (Figure 2F). These data suggest that SDF-1 secreted from bone
cells plays a key role in the secretion of IL-6 in SCC cells.
ERK signaling pathway is involved in SDF-1a-mediated IL-6
upregulation
As SDF-1a–CXCR4 interaction has been shown to activate several
signaling pathways, including phosphatidylinositol 3-kinase/protein
kinase B (Akt) and mitogen-activated protein kinase (MAPK), in
various cell lines (23,24). We performed western blot analysis to
elucidate the signal transduction mechanisms involved in the SDF-
1a-induced upregulation of IL-6. SDF-1a activated the ERK1/2 path-
way in SCC4 cells, as evidenced by the increase in phosphorylated
p42 and p44 (p-ERK) (Figure 3A). Other signaling pathways includ-
ing p38 MAPK, JNK and Akt were not activated up to 2 h after
treatment (Figure 3A). SDF-1a-induced IL-6 production was greatly
reduced by treatment with the ERK inhibitor PD98059 (10 lM), but
was not affected by SB203580 (a p38 MAPK inhibitor; 10 lM),
SP600125 (a JNK inhibitor; 10 lM) or Akt inhibitor (10 lM) (Figure
3B). In addition, transfection of cells with ERK2 but not p38, JNK or
Akt mutants also antagonized the potentiating effects of SDF-1a
(Figure 3C). Taken together, these data suggest that the activation
of the ERK pathway is required for the SDF-1a-induced increase of
IL-6 in human SCC cells.
Involvement of NF-jB in SDF-1a-induced IL-6 production
There are NF-jB- and AP-1-binding sites on this IL-6 promoter re-
gion (32,35). The increase of IL-6 production by SDF-1a was antag-
onized by cis element decoy agonist NF-jB-binding site (decoy
NF-jB ODN) but not by AP-1-binding site (decoy AP-1 ODN) or
scrambled decoy (ODN) (Figure 4A). NF-jB activation has been
reported to be necessary for IL-6 induction in macrophages (32). To
examine whether NF-jB activation is involved in the signal trans-
duction pathway leading to IL-6 expression caused by SDF-1a, the
NF-jB inhibitor PDTC was used. Figure 4B shows that PDTC
(30 lM) inhibited the enhancement of IL-6 production induced by
SDF-1a. Furthermore, pretreatment of SCC cells withan IjB protease
inhibitor [L-1-tosylamido-2-phenylenylethyl chloromethyl ketone
(3 lM)] and NF-jB inhibitor peptide (10 lg/ml) also antagonized
the potentiating action of IL-6 (Figure 4B). It has been reported that
the NF-jB binding site between  72 and  63 was important for the
activation of the IL-6 gene (32). NF-jB activation was further eval-
uated by analyzing the translocation of NF-jB from cytosol to the
nucleus, as well as by chromatin immunoprecipitation assay. Treat-
ment of cells with SDF-1a resulted in a marked translocation of p65
and p50 NF-jB from the cytosol to the nucleus (Figure 4C). The
in vivo recruitment of p65 and p50 to the IL-6 promoter ( 288
to  39) was assessed by chromatin immunoprecipitation assay.
In vivo binding of p65 and p50 to the NF-jB element of the IL-6
promoter occurred as early as 15 min and was sustained to 120 min
after SDF-1a stimulation (Figure 4D). The binding of p65 and p50
to NF-jB element by SDF-1a stimulation was attenuated by
AMD3100 and PD98059 but not SB203580, SP600125 and Akt in-
hibitor (Figure 4E). To further conﬁrm the NF-jB element involved in
the action of SDF-1a-induced IL-6 expression, transient transfection
was performed using the jB promoter–luciferase constructs. SCC4
cells incubated with SDF-1a (100 ng/ml) led to a 3.3-fold increase in
jB promoter activity. The increase of jB activity by SDF-1a was
antagonized by AMD3100 and PD98059 but not SB203580,
SP600125 and Akt inhibitor (Figure 4F). These results suggest that
NF-jB activation is necessary for SDF-1a-induced IL-6 production in
human SCC cells.
Fig. 3. ERK is involved in the potentiation of IL-6 expression by SDF-1a. SCC4 cells were incubated with SDF-1a (100 ng/ml) for indicated time intervals, and
p-ERK, p-p38, p-JNK or p-Akt expression was determined by western blot analysis (A). Cell were pretreated for 30 min with PD98059 (10 lM), SB203580 (10
lM), SP600125 (10 lM) and Akt inhibitor (10 lM) (B) or transfected with dominant-negative (DN) mutant of ERK, p38, JNK and Akt (C) for 24 h followed by
stimulationwithSDF-1a (100ng/ml)for24h. MediawerecollectedtomeasureIL-6.Resultsareexpressedasthe mean±SE.  P,0.05ascomparedwithvehicle.
#P , 0.05 as compared with SDF-1a-treated group.
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phosphorylation
We further examined the upstream molecules involved in SDF-1a-
induced NF-jB activation. Stimulation of cells with SDF-1a induced
IKKa/b phosphorylation in a time-dependent manner (Figure 5A).
Treatment of SCC cells with SDF-1a also caused IjBa phosphoryla-
tion in a time-dependent manner (Figure 5B). Next, we further exam-
ined p65 phosphorylation at Ser276 by SDF-1a in SCC cells.
Treatment of cells with SDF-1a induced p65 phosphorylation at
Ser276 in a time-dependent manner (Figure 5C). Furthermore, trans-
fection with IKKa or IKKb mutant markedly inhibited SDF-1a-
induced IL-6 production (Figure 5D). Pretreatment of cells with
AMD3100 or PD98059 attenuated SDF-1a-induced IjBa, IKKa/b
and p65 phosphorylation (Figure 5E). These data suggest that
IKKa/b and p65 activation is involved in SDF-1a-induced IL-6 pro-
duction in human SCC cells.
Conditioned medium from SCC4 supports osteoclast differentiation
Forty-eight hour-conditioned medium (containing serum) from SCC4
cells diluted 50% in Dulbecco’s modiﬁed Eagle’s medium was added
to cultures of human PBMCs. SCC4-conditioned medium stimulated
osteoclast formation by using TRAP staining (Figure 6A, upper
Fig. 4. NF-jB is involved in the potentiation of IL-6 production by SDF-1a.( A) SCC4 cells were transfected with NF-jB ODN, AP-1 ODN or scramble ODN
before incubation with SDF-1a (100 ng/ml) for 24 h. Media were collected to measure IL-6. (B) Cells were pretreated for 30 min with PDTC (60 lM), L-1-
tosylamido-2-phenylenylethyl chloromethyl ketone (3 lM) and NF-jB inhibitor peptide (10 lg/ml) followed by stimulation with SDF-1a (100 ng/ml) for 24 h.
Media were collected to measure IL-6. Results of four independent experiments performed in triplicate are expressed.  P , 0.05 as compared with control. #P ,
0.05 as compared with SDF-1a-treated group. (C) Cells were treated with SDF-1a (100 ng/ml) for indicated time intervals, and the levels of cytosolic and nuclear
p65 or p50 were determined by immunoblotting with p65 or p50 speciﬁc antibodies, respectively. (D and E) Cells were treated with SDF-1a (100 ng/ml) for the
indicated time intervals or pretreated with AMD3100 (500 ng/ml), PD98059 (10 lM), SB203580 (10 lM), SP600125 (10 lM) and Akt inhibitor (10 lM) and then
stimulatedwith SDF-1a (100 ng/ml)for 60 min, and chromatinimmunoprecipitation assay was thenperformed.Chromatinwas immunoprecipitated with anti-p65
or anti-p50 antibody. One percent of the precipitated chromatin was assayed to verify equal loading (input). (F) Cells were transfected with jB-luciferase
expression vector and then pretreated with AMD3100 (500 ng/ml), PD98059 (10 lM), SB203580 (10 lM), SP600125 (10 lM) and Akt inhibitor (10 lM) for 30
min before incubation with SDF-1a (100 ng/ml) for 24 h. Luciferase activity was then assayed. Results are representative of at least three independent
experiments.  P , 0.05 as compared with control. #P , 0.05 as compared with SDF-1a-treated group.
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1488panel). In addition, the TRAP-positive multinucleated cells expressed
the resorbing activity (Figure 6A, lower panel). On the other hand,
the control medium did not increase the osteoclastogenesis (A549-
conditioned medium was used for positive control) (34) (Figure 6B).
These data suggest that SCC4 cells secrete factors that stimulate oste-
oclast formation. We next investigated whether the effects on osteo-
clasts of SCC4-conditioned medium were due to IL-6 production by
tumor cells using commercially available IL-6-neutralizing antibody.
The antibodies signiﬁcantly reduced the number of osteoclasts induced
by conditioned medium from SCC4 (Figure 6C). However, IL-6 anti-
body treatment did not fully suppress osteoclast formation to control
levels (Figure6C), suggesting that SCC4 supports osteoclast formation
by IL-6-dependent and IL-6-independent mechanisms. We next exam-
ined the IL-6-independent component of the pro-osteoclastogenic ac-
tivity secretedbySCC4cells.RANKL,acentralregulatorofosteoclast
formation andactivity (36), was an obvious candidate factor for the IL-
6-independentcomponent.RANK-Fc(200ng/ml)wasaddedtoSCC4-
conditioned medium blocking SCC4-conditioned medium-induced
osteoclast formation (Figure 6D). The IL-6 antibody plus RANKL-Fc
completely blocked the SCC4-conditioned medium-induced osteoclast
formation. These data suggest that secreted RANKL is responsible for
the IL-6-independent effects on osteoclast formation. On the other
hand, both transforming growth factor-b1 and IL-1 antibodies had no
effect on SCC4-conditioned medium-induced osteoclast formation.
Discussion
Oral carcinomas, especially oral SCC, frequently invade into maxil-
lary or mandibularbone, and bone invasion is a more common clinical
problem in patients with oral carcinomas. However, its mechanism is
poorly understood. Recent studies have revealed that bone resorption
by osteoclasts is an important step in the process of bone invasion and
metastasis in several malignancies including oral carcinomas (1–3).
Although various cytokines, i.e. IL-1, IL-6, IL-11, transforming
growth factor, tumor necrosis factor and parathyroid hormone-related
protein have been shown to activate osteoclastic bone resorption
(31,37), it remains unclear whether these cytokines that can be pro-
duced by tumor cells may be directly involved in bone invasion and
metastasis of malignancies. Only parathyroid hormone-related protein
has been reported to play an important role in the formation of bone
metastasis of human lung and breast carcinoma cells (2).
IL-6 is expressed by a number of cancer cell lines in vitro.
A correlation is observed between tumor cell expression of IL-6
and metastatic potential (38). Here, we found that human SCC
(HSC3, SCC4 and SCC9) expressed IL-6 mRNA and protein. We
hypothesized that SDF-1 and its CXCR4 receptor would help to direct
the bone-speciﬁc invasion of oral SCC cells. In this study, we found
that osteoblast-derived SDF-1 induced expression of IL-6 in human
SCC cells. Overexpression of human full-length CXCR4 increased
SDF-1-induced IL-6 production. We also used CXCR4-speciﬁc
chemical inhibitor AMD3100 and CXCR4-neutralizing antibody to
determine the role of CXCR4 and found that it inhibited SDF-1a-
induced IL-6 expression, indicating the possible involvement of
CXCR4 in SDF-1a-induced IL-6 expression in SCC cells. This was
further conﬁrmed by the result that the siCXCR4 inhibited the en-
hancement of IL-6 production by SDF-1a, indicating the involvement
of SDF-1–CXCR4 interaction in SDF-1a-mediated induction of IL-6.
A variety of growth factors stimulate the expression of IL-6 genes
via signal transduction pathways that converge to activate NF-jB
complex of transcription factors. MAPK pathways ERK1/2, JNK
and p38 induce the expression of NF-jB transcription factors (39).
We found that SDF-1a enhanced ERK1/2 phosphorylation without
obvious changes of the phosphorylation of Akt and other MAPK
pathways (e.g. JNK and p38) in human SCC cells. Previous studies
have revealed that SDF-1a treatment activates ERK1/2 in human lung
cancer cells, astrocytes and glioblastoma cells (19,21,40). The SDF-
1a-directed IL-6 production was effectively inhibited by PD98059,
but not by SB203580, SP600125 or the Akt inhibitor. This was further
conﬁrmed by the results that the dominant-negative mutant of ERK,
but not p38, JNK and Akt, inhibited the enhancement of IL-6 pro-
duction by SDF-1a. Recently, hepatitis B viral HBx was shown to
induce matrix metalloproteinase-9 (MMP-9) gene expression through
the activation of the ERK and Akt pathways (41). Liang et al. (42)
suggested that the ERK pathway was required for IL-1-induced
MMP-9 expression. Our data indicate that ERK might play an impor-
tant role in the expression of IL-6 of human SCC cells.
Fig. 5. SDF-1ainducesIKKa/bactivation,IjBaphosphorylationandp65Ser276 phosphorylationinSCC cells.SCC4cells wereincubatedwithSDF-1a (100ng/ml)
for indicated time intervals; cell lysates were then immunoblotted with an antibody speciﬁc for phosphor-IKKa/b (A), phosphor-IjBa (B) and p65 phosphorylated
at Ser276 (C) antibodies, respectively. Cells were transfected with IKKa, IKKb mutant or vector for 24 h followed by stimulation with SDF-1a for 24 h. Media
were collected to measure IL-6 (D). Results are representative of at least three independent experiments.  P , 0.05 as compared with control. #P , 0.05 as
compared with SDF-1a-treated group. Cells were pretreated with AMD3100 (500 ng/ml) or PD98059 (10 lM) and then stimulated with SDF-1a (100 ng/ml) for
60 min, and phosphor-IKKa/b, phosphor-IjBa and p65 phosphorylated at Ser276 were then determined by western blot (E).
Bone-derived SDF stimulates IL-6 expression
1489Fig. 6. Conditioned medium from SCC4 cells supports osteoclast differentiation. Conditioned medium from SCC4 cells was added to culture of PBMC. Half the
medium was replaced thrice per week and cultures were terminated on day 10. The plates were stained for TRAP (A, upper panel). On the other hand, the PBMCs
were cultured on osteoclast activity assay substrate plate and the cells were removed after 10 days (A, lower panel). The arrow heads show the osteoclast resorbing
pit. (B) Control medium, control medium plus macrophage colony-stimulating factor, SCC4-conditioned medium or A549-conditioned medium was added to
culture of PBMC. Half the medium was replaced thrice per week and cultures were terminated on day 10. The plates were stained for TRAP. Note that SCC4- and
A549-conditioned medium but not control medium stimulated TRAP-positive multinucleated cell. (C) Anti-IL-6 antibody (200 lg/ml) but not isotype IgG
inhibited the SCC4-conditioned medium-induced osteoclastogenesis. (D) IL-6 antibody (200 lg/ml), RANKL-Fc (200 ng/ml), IL-6 antibody plus RANKL-Fc,
transforming growth factor-b antibody (200 lg/ml), IL-1 antibody (200 lg/ml) were added to SCC4-conditioned medium; IL-6 antibody, RANKL-Fc, IL-6
antibody plus RANKL-Fc but not TGF-b or IL-1 antibody blocked the SCC4-conditioned medium-induced osteoclastogenesis.  P , 0.05 as compared with
control. #P , 0.05 as compared with IgG-treated group. (E) Schematic representation of the signaling pathways involved in the osteoblast-derived SDF-1a-
induced IL-6 production and promotion of osteoclastogensis in human SCC cells. Osteoblasts release SDF-1a and then activate CXCR4, ERK and IKKa/b,
leading to the activation of NF-jB on the IL-6 promoter, initiation of IL-6 mRNA and protein release and promotion of osteoclastogenesis.
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including NF-jB, cAMP response element-binding protein, NF-IL-6
and AP-1 box in the 5# region of the IL-6 gene (32,35). To date, two
transcription factors (NF-jB and the AP-1) appear to be responsive to
the SDF-1 (43). In this study, NF-jB but not AP-1 modulated SDF-
1a-induced IL-6 activity in SCC cells. The results of this study also
show that NF-jB activation contributes to SDF-1a-induced IL-6 pro-
ductioninSCCcellsandthattheinhibitorsoftheNF-jB-dependentsig-
naling pathway, including PDTC, L-1-tosylamido-2-phenylenylethyl
chloromethyl ketone or NF-jB inhibitor peptide, inhibited SDF-1a-
induced IL-6 expression. In an inactivated state, NF-jB is normally
held in the cytoplasm by the inhibitor protein IjB. Upon stimulation,
such as by tumor necrosis factor-a,I jB proteins become phosphory-
lated by the multisubunit IKK complex, which subsequently targets
IjB for ubiquitination, and then are degraded by the 26S proteasome.
Finally, the free NF-jB translocates to the nucleus, where it activates
the responsive gene. In the present study, we found that treatment of
SCC4 cells with SDF-1a resulted in increases in IKKa/b phosphory-
lation and activity, p65 and p50 translocation from the cytosol to the
nucleus and the binding of p65 and p50 to the NF-jB element on the
IL-6 promoter. Using transient transfection with jB-luciferase as an
indicator of NF-jB activity, we also found that SDF-1a induced an
increase in NF-jB activity. The IKKs can be stimulated by various
proinﬂammatory stimuli, including IL-1b, peptidoglycan and throm-
bin (44). These extracellular signals activate the IKK complex, which
is comprised of catalytic subunits (IKKa and IKKb) and a linker sub-
unit(IKKc/NEMO).ThiskinasecomplexinturnphosphrylatesIjBaat
Ser32 and Ser36 and signals for ubiquitin-related degradation. The re-
leased NF-jB is then translocated into the nucleus where it promotes
NF-jB-dependent transcription. The ﬁndings of our experiments
show that pretreatment of SCC4 cells with AMD3100 or PD98059
antagonized the increase of IjBa, IKKa/b and p65 phosphorylation
by SDF-1a. Based on these ﬁndings, we suggest that the CXCR4/
ERK pathway is involved in SDF-1a-induced IjBa, IKKa/b and
p65 activation. Similar ﬁndings have reported that the activation of
p-ERK precedes and is required for activation of IKKa/b, p65 and
NF-jB (45,46). Our previous data showed that SDF-1a enhanced
motility and upregulated MMP-9 and b3 integrin via ERK/IKKab
and NF-jB pathway in human lung cancer cells (45,46). Here, we
also found that ERK or NFjB inhibitors and IKKa or IKKb mutants
also inhibited the SDF-1a-induced motility and upregulated MMP-9
and b3 integrin in SCC4 cells (data not shown). Therefore, the same
signaling pathway mediates the motility and the expression of MMP-9
and integrins in SCC cells.
In conclusion, we present here a novel mechanism of SDF-1a/
CXCR4-directed invasion of oral SCC cells by upregulation of IL-6
production and promotion of osteoclastogenesis. The identiﬁcation of
SDF-1a from bone as a potential stimulatory factor of IL-6 during
human cancer cell invasion to bone and promotion of osteoclasto-
genesis may help understand the mechanisms involved in the aggres-
sive potential of human SCC cells (Figure 6E). In addition, the
identiﬁcation of SDF-1a–CXCR4 interaction as an important factor
in the invasiveness of human SCC cells may implicate potential ther-
apeutic approaches for bone invasion from oral SCC cells.
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